PNC Financial Services Group’s Kailera Therapeutics KLRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.68K Sell
235
-2,407
-91% -$40.7K ﹤0.01% 4742
2026
Q2
$58.2K Buy
+2,642
New +$58.1K ﹤0.01% 3253

Other funds holding KLRA

PNC Financial Services Group's KLRA Position: Q3 2026 in Review

PNC Financial Services Group reduced its Kailera Therapeutics (KLRA) stake by 91% in Q3 2026, selling an estimated $40.7K and leaving 235 shares worth $2.68K. The position accounts for ﹤0.01% of the portfolio, ranked #4742.

PNC Financial Services Group first reported a position in KLRA in Q2 2026 and has held it in 2 quarters since. The position peaked at $58.2K in Q2 2026. 132 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.

  • PNC Financial Services Group held 235 shares of Kailera Therapeutics worth $2.68K as of Q3 2026.
  • PNC Financial Services Group sold 2,407 Kailera Therapeutics shares in Q3 2026, an estimated $40.7K.
  • Kailera Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4742 holding.
  • PNC Financial Services Group first reported a position in Kailera Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • PNC Financial Services Group's Kailera Therapeutics position peaked at $58.2K in Q2 2026.
  • 132 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.